Phenibut Pharmacology — Receptor-Level Overview

Scientific Reference

Phenibut Pharmacology — Receptor-Level & Enantiomer Overview

This page summarizes, at a neutral mechanistic level, how the peer-reviewed literature describes phenibut’s molecular pharmacology and stereochemistry. It is reference science for researchers characterizing the compound. It is not usage, dosage, effects, or medical guidance of any kind.

Molecular targets

• GABA-B receptor agonism — phenibut is described as an agonist at the metabotropic GABA-B receptor (the same receptor family as baclofen).
• α₂δ voltage-dependent calcium channel subunit — it also binds the α₂δ subunit targeted by the gabapentinoids (gabapentin, pregabalin). Phenibut is therefore correctly classified as a gabapentinoid as well as a GABA-B agonist.
• Other — weak dopaminergic activity is reported in older studies (preliminary/unresolved).

A widely repeated claim that phenibut has meaningful GABA-A activity is now considered overstated: an 85-target receptor screen (Belozertseva et al., 2016) found little activity outside its narrow target profile.

Binding affinity (from the peer-reviewed literature)

• Racemic phenibut — GABA-BK_i ≈ 177 µM (Dambrova 2008)
• R-phenibut — GABA-BK_i ≈ 92 µM
• S-phenibut — GABA-Bno binding detected
• Baclofen — GABA-B (reference)K_i ≈ 6 µM
• R-phenibut — α₂δK_i ≈ 23 µM (Zvejniece 2015)
• S-phenibut — α₂δK_i ≈ 39 µM
• Gabapentin — α₂δ (reference)K_i ≈ 0.05 µM

Two facts follow from these data: phenibut is roughly 30-fold less potent than baclofen at GABA-B, and R-phenibut binds the α₂δ subunit several-fold more tightly than it binds GABA-B — so the “GABA-B compound” description captures only part of its pharmacology.

Enantiomers — the key stereochemical finding

The stereochemistry was established chiefly by the Latvian Institute of Organic Synthesis:

• Dambrova et al. (2008), Eur J Pharmacol — in behavioural assays the S-enantiomer was inactive while the R-enantiomer carried the activity; a GABA-B antagonist blocked R-phenibut’s effects, confirming GABA-B mediation. The activity of racemic phenibut is essentially the activity of R-phenibut.
• Zvejniece et al. (2015), Pharmacol Biochem Behav — R-phenibut binds α₂δ and its anti-nociceptive effects in animal models are α₂δ-mediated, gabapentin-like.
• Belozertseva et al. (2016), Pharmacol Rep — independent replication of α₂δ binding for both isomers.

Practical implication for characterization: commercial and pharmaceutical phenibut is racemic (see stereochemistry), so roughly half of the material is the S-enantiomer, which contributes little at GABA-B.

Pharmacokinetics (characterization)

• Elimination half-life~5.3 h reported from a single-dose study (preliminary)
• Metabolismminimal hepatic; reported metabolites inactive
• Excretionlargely renal, unchanged; clearance reported to track creatinine clearance

Because clearance is reported to follow renal function, impaired renal function would be expected to prolong exposure — a handling and hazard consideration, not a dosing statement. For hazard information see Safety & Toxicology.

References

• Dambrova M, et al. Comparative pharmacological activity of optical isomers of phenibut. Eur J Pharmacol. 2008;583(1):128–134.
• Zvejniece L, et al. R-phenibut binds to the α₂δ subunit… Pharmacol Biochem Behav. 2015;137:23–29.
• Belozertseva I, et al. Optical isomers of phenibut inhibit [3H]-gabapentin binding… Pharmacol Rep. 2016;68:550–554.

For Research Use Only. Not for human or animal consumption. This page is regulatory/scientific reference. Nothing here is medical advice, dosage, or usage guidance, and no statement has been evaluated by the U.S. FDA. See our Disclaimer.